Literature DB >> 19089805

MAP dendrimer elicits antibodies for detecting rat and mouse GH-binding proteins.

Roberto M Aguilar1, Frank J Talamantes, Juan J Bustamante, Jesus Muñoz, Lisa R Treviño, Andrew O Martinez, Luis S Haro.   

Abstract

The membrane-bound rat GH-R and an alternatively spliced isoform, the soluble rat GH-BP, are comprised of identical N-terminal GH-binding domains; however, their C-terminal sequences differ. Immunological reagents are needed to distinguish between the two isoforms in order to understand their respective roles in mediating the actions of GH. Accordingly, a tetravalent MAP dendrimer with four identical branches of a C-terminal peptide sequence of the rat GH-BP (GH-BP(263-279)) was synthesized and used as an immunogen in rabbits. Solid-phase peptide synthesis of four GH-BP(263-279) segments onto a tetravalent Lys(2)-Lys-beta-Ala-OH core peptide was carried out using Fmoc chemistry. The mass of the RP-HPLC-purified synthetic product, 8398 Da, determined by ESI-MS, was identical to expected mass. Three anti-rat GH-BP(263-279) MAP antisera, BETO-8039, BETO-8040, and BETO-8041, at dilutions of 10(-3), recognized both the rat GH-BP(263-279) MAP and recombinant mouse GH-BP with ED(50)s within a range of 5-10 fmol, but did not cross-react with BSA in dot blot analyses. BETO-8041 antisera (10(-3) dilution) recognized GH-BPs of rat serum and liver having M(r)s ranging from 35 to 130 kDa, but did not recognize full-length rat GH-Rs. The antisera also detected recombinant mouse GH-BPs. In summary, the tetravalent rat GH-BP(263-279) MAP dendrimer served as an effective immunogenic antigen in eliciting high titer antisera specific for the C-termini of both rat and mouse GH-BPs. The antisera will facilitate studies aimed at improving our understanding of the biology of GH-BPs. (c) 2008 European Peptide Society and John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19089805      PMCID: PMC2745905          DOI: 10.1002/psc.1096

Source DB:  PubMed          Journal:  J Pept Sci        ISSN: 1075-2617            Impact factor:   1.905


  58 in total

Review 1.  Methods and strategies of peptide ligation.

Authors:  J P Tam; J Xu; K D Eom
Journal:  Biopolymers       Date:  2001       Impact factor: 2.505

2.  Liposome entrapment and immunogenic studies of a synthetic lipophilic multiple antigenic peptide bearing VP1 and VP3 domains of the hepatitis A virus: a robust method for vaccine design.

Authors:  Isabel Haro; Silvia Pérez; Mónica García; Weng C Chan; Guadalupe Ercilla
Journal:  FEBS Lett       Date:  2003-04-10       Impact factor: 4.124

Review 3.  Growth hormone receptor/binding protein (GHR/BP) knockout mice: a 3-year update.

Authors:  E O List; K T Coschigano; J J Kopchick
Journal:  Mol Genet Metab       Date:  2001-05       Impact factor: 4.797

Review 4.  Peptide dendrimers: applications and synthesis.

Authors:  Kristen Sadler; James P Tam
Journal:  J Biotechnol       Date:  2002-05       Impact factor: 3.307

5.  Growth hormone (GH) and estradiol regulation of membrane-associated GH binding protein and GH receptors in GH releasing hormone transgenic mice.

Authors:  L González; A I Sotelo; A Bartke; D Turyn
Journal:  Growth Horm IGF Res       Date:  2001-02       Impact factor: 2.372

6.  Immune growth hormone (GH): localization of GH and GH mRNA in the bursa of Fabricius.

Authors:  M Luna; A J Rodríguez-Méndez; L Berumen; M Carranza; J Riesgo-Escovar; M-L Baudet; S Harvey; C Arámburo
Journal:  Dev Comp Immunol       Date:  2008-05-21       Impact factor: 3.636

Review 7.  Orthogonal ligation strategies for peptide and protein.

Authors:  J P Tam; Q Yu; Z Miao
Journal:  Biopolymers       Date:  1999       Impact factor: 2.505

8.  Structurally distinct membrane-associated and soluble forms of GH-binding protein in the mouse.

Authors:  R J Cerio; F Xing; R J Fatula; D E Keith; X Yang; F Talamantes; J N Southard; J N Southard
Journal:  J Endocrinol       Date:  2002-02       Impact factor: 4.286

9.  Deletion, but not antagonism, of the mouse growth hormone receptor results in severely decreased body weights, insulin, and insulin-like growth factor I levels and increased life span.

Authors:  Karen T Coschigano; Amy N Holland; Markus E Riders; Edward O List; Allan Flyvbjerg; John J Kopchick
Journal:  Endocrinology       Date:  2003-09       Impact factor: 4.736

Review 10.  Growth hormone binding protein. The soluble growth hormone receptor.

Authors:  G Baumann
Journal:  Minerva Endocrinol       Date:  2002-12       Impact factor: 2.184

View more
  3 in total

1.  Novel monodisperse PEGtide dendrons: design, fabrication, and evaluation of mannose receptor-mediated macrophage targeting.

Authors:  Jieming Gao; Peiming Chen; Yashveer Singh; Xiaoping Zhang; Zoltan Szekely; Stanley Stein; Patrick J Sinko
Journal:  Bioconjug Chem       Date:  2013-08-21       Impact factor: 4.774

2.  Immunization with a novel chimeric peptide representing B and T cell epitopes from HER2 extracellular domain (HER2 ECD) for breast cancer.

Authors:  Manijeh Mahdavi; Mehrnaz Keyhanfar; Abbas Jafarian; Hassan Mohabatkar; Mohammad Rabbani
Journal:  Tumour Biol       Date:  2014-08-21

3.  Growth hormone responsive neural precursor cells reside within the adult mammalian brain.

Authors:  Daniel G Blackmore; Brent A Reynolds; Mohammad G Golmohammadi; Beatrice Large; Roberto M Aguilar; Luis Haro; Michael J Waters; Rodney L Rietze
Journal:  Sci Rep       Date:  2012-02-07       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.